Table 3.
Two-year overall survival according to enrollment period
| 2-year overall survival (%, 95% CI) |
|||||
|---|---|---|---|---|---|
| Pre-cART (1990–1995) (N = 388) | cART (1996–2010) (N = 1158) | Early (1996–2000) (N = 694) | Recent (2001–2004) (N = 282) | Contemporary (2005–2010) (N = 182) | |
| Histology | |||||
| DLBCL | 24 (19–30) | 57 (53–61) | 51 (46–55) | 67 (60–73) | 67 (56–76) |
| BL/BLL | 37 (28–47) | 55 (49–60) | 45 (36–53) | 46 (32–58) | 75 (65–82) |
| CD4 count | |||||
| <50 cells/mm3 | 13 (5–25) | 34 (27–42) | 24 (15–34) | 36 (22–50) | 65 (43–80) |
| ≥50 cells/mm3 | 30 (25–35) | 60 (56–63) | 53 (48–57) | 68 (61–74) | 73 (65–79) |
| aaIPI | |||||
| Low | 57 (41–70) | 74 (64–82) | 65 (51–76) | 86 (55–96) | 100 (100–100) |
| Intermediate | 27 (22–33) | 58 (54–62) | 51 (46–56) | 68 (60–75) | 77 (66–85) |
| High | 15 (8–25) | 40 (33–48) | 29 (20–39) | 51 (37–63) | 49 (34–63) |
cART, combination antiretroviral therapy; DLBCL, diffuse large B-cell lymphoma; BL, Burkitt lymphoma; BLL, Burkitt-like lymphoma; aaIPI, age-adjusted International Prognostic Index.